ArticleArchives of virology2026
Immunogenicity of an inactivated vaccine against senecavirus a and duration of the immune response in pigs.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Senecavirus A (SVA) infection causes vesicular disease in pigs, resulting in significant economic losses for swine producers and trade restrictions on pork exports. Due to its clinical similarity to other vesicular diseases, implementing control measures, such as vaccination, is essential to mitigate the impact of the disease. In this study, we assessed the immunogenicity of an inactivated SVA vaccine derived from a representative strain circulating in Brazil and the duration of vaccine-induced immunity in swine. Vaccinated 6- to 8-week-old pigs exhibited a robust humoral response, evidenced by significant increases in SVA-specific IgG and virus-neutralizing antibody titers. These humoral responses were detectable as early as seven days after primary vaccination and persisted for at least 11 weeks. Regarding cellular immunity, vaccinated pigs exhibited significantly higher proliferation of B lymphocyte subpopulations (CD19
Indexed as
Identifiers
41501219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.